

C John Sperati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6419436/publications.pdf>

Version: 2024-02-01

53
papers

1,524
citations

394286

19
h-index

315616

38
g-index

53
all docs

53
docs citations

53
times ranked

2409
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions. <i>Circulation</i> , 2014, 129, 1048-1078.	1.6	367
2	Tuberculosis-associated haemophagocytic syndrome. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 447-454.	4.6	154
3	Modified Ham test for atypical hemolytic uremic syndrome. <i>Blood</i> , 2015, 125, 3637-3646.	0.6	88
4	Reoxygenation of Hypoxic Human Umbilical Vein Endothelial Cells Activates the Classic Complement Pathway. <i>Circulation</i> , 1997, 96, 326-333.	1.6	79
5	Eculizumab cessation in atypical hemolytic uremic syndrome. <i>Blood</i> , 2017, 130, 368-372.	0.6	70
6	Variable Clinical Presentation of an MUC1 Mutation Causing Medullary Cystic Kidney Disease Type 1. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 527-535.	2.2	65
7	Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. <i>JCI Insight</i> , 2018, 3, .	2.3	65
8	The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. <i>BMC Nephrology</i> , 2020, 21, 449.	0.8	61
9	Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. <i>Blood</i> , 2019, 134, 1037-1045.	0.6	58
10	Primary Care Physiciansâ€™ Perceived Barriers to Nephrology Referral and Co-management of Patients with CKD: a Qualitative Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 1228-1235.	1.3	51
11	Primary care physiciansâ€™ perceptions of barriers and facilitators to management of chronic kidney disease: A mixed methods study. <i>PLoS ONE</i> , 2019, 14, e0221325.	1.1	48
12	A detailed analysis of methylmalonic acid kinetics during hemodialysis and after combined liver/kidney transplantation in a patient with <i>mut</i> ⁰ methylmalonic acidemia. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 899-907.	1.7	40
13	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
14	Drug Interactions and Antiretroviral Drug Monitoring. <i>Current HIV/AIDS Reports</i> , 2014, 11, 212-222.	1.1	38
15	Predictors of Complication after Percutaneous Ultrasound-Guided Kidney Biopsy in HIV-Infected Individuals. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1766-1773.	2.2	31
16	Thrombotic Microangiopathy. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 541-559.	0.9	25
17	Hydroxychloroquine-induced mimic of renal Fabryâ€™disease. <i>Kidney International</i> , 2018, 94, 634.	2.6	25
18	Feasibility and Safety of Physical Therapy during Continuous Renal Replacement Therapy in the Intensive Care Unit. <i>Annals of the American Thoracic Society</i> , 2016, 13, 699-704.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Association of Single-Nucleotide Polymorphisms in JAK3, STAT4, and STAT6 With New Cardiovascular Events in Incident Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2009, 53, 845-855.	2.1	19
20	The Impact of Hepatitis C Coinfection on Kidney Disease Related to Human Immunodeficiency Virus (HIV). <i>Medicine (United States)</i> , 2011, 90, 289-295.	0.4	19
21	Fibromuscular dysplasia. <i>Kidney International</i> , 2009, 75, 333-336.	2.6	16
22	Inhibiting calpain 1 and 2 in cyclin G associated kinase "knockout mice mitigates podocyte injury. <i>JCI Insight</i> , 2020, 5, .	2.3	15
23	Stabilization of Hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon γ -2a and ribavirin. <i>Clinical Nephrology</i> , 2013, 80, 231-234.	0.4	15
24	Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag. <i>American Journal of Hematology</i> , 2010, 85, 724-726.	2.0	14
25	A novel bedside cardiopulmonary physical diagnosis curriculum for internal medicine postgraduate training. <i>BMC Medical Education</i> , 2017, 17, 182.	1.0	14
26	Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. <i>Blood Advances</i> , 2021, 5, 1504-1512.	2.5	13
27	Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2020, 98, 1265-1274.	2.6	10
28	Urinary fractional excretion indices in the evaluation of acute kidney injury. <i>Journal of Hospital Medicine</i> , 2016, 11, 77-80.	0.7	9
29	The Hyperlipidemia Effect: Pseudohyponatremia in Pancreatic Cancer. <i>American Journal of Medicine</i> , 2017, 130, 1372-1375.	0.6	8
30	What the non-nephrologist needs to know about dialysis. <i>Seminars in Dialysis</i> , 2018, 31, 183-192.	0.7	8
31	Ex vivo assays to detect complement activation in complementopathies. <i>Clinical Immunology</i> , 2020, 221, 108616.	1.4	7
32	Racial-Ethnic Differences in Health-Related Quality of Life among Adults and Children with Glomerular Disease. <i>Glomerular Diseases</i> , 2021, 1, 105-117.	0.2	6
33	Raman Spectroscopy for the Diagnosis of Intratubular Triamterene Crystallization. <i>Kidney International Reports</i> , 2018, 3, 997-1003.	0.4	5
34	Improving Primary Care Delivery for Patients Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021, 78, 886-891.	2.1	3
35	How I Treat Complement-Mediated TMA. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.13581021.	2.2	3
36	Incidental Discovery of a Renal Cell Carcinoma on Native Kidney Biopsy. <i>American Journal of Kidney Diseases</i> , 2010, 56, 175-180.	2.1	2

#	ARTICLE	IF	CITATIONS
37	Hemodialysis: Initiation and Complications. , 2013, , 333-348.		2
38	Quiz Page January 2014. American Journal of Kidney Diseases, 2014, 63, A18-A21.	2.1	2
39	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	2
40	The Tissue's the Issue. American Journal of Medicine, 2010, 123, 420-422.	0.6	1
41	All Wrapped up and Nowhere to Flow. American Journal of Medicine, 2012, 125, 876-879.	0.6	1
42	Higher Prevalence of Concurrent Thrombocytopenia in Patients Receiving Continuous Renal Replacement Therapy in the Cardiac Intensive Care Unit. Blood Purification, 2021, 50, 891-898.	0.9	1
43	Renal vein thrombosis and pulmonary embolism. Cleveland Clinic Journal of Medicine, 2018, 85, 833-834.	0.6	1
44	O Complement, Where Aren't Thou. Advances in Chronic Kidney Disease, 2020, 27, 83-85.	0.6	1
45	Response to "Causative vascular abnormalities for renal ischemia". Kidney International, 2009, 75, 1354.	2.6	0
46	Novel therapeutics in hypertension and kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 401-402.	1.0	0
47	Secondary Hypertension: Beginnings and Transitions. Advances in Chronic Kidney Disease, 2015, 22, 177-178.	0.6	0
48	From Dropsy to Chart Biopsy: Opportunities and Pitfalls of Electronic Health Records. Kidney360, 2021, 2, 1399-1401.	0.9	0
49	Î²-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome. Blood, 2016, 128, 3818-3818.	0.6	0
50	Egad!. Journal of Hospital Medicine, 2019, 14, 181.	0.7	0
51	A Night Float System in Nephrology Fellowship: A Mixed Methods Evaluation. Kidney360, 2020, 1, 631-639.	0.9	0
52	Cystic Kidneys in a Patient with Craniofacial Abnormalities. Kidney360, 2020, 1, 882-883.	0.9	0
53	A young man with hypertension and hypokalemia. Cleveland Clinic Journal of Medicine, 2020, 87, 77-79.	0.6	0